3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
291
Carcinoma, Non-Small-Cell Lung
222
Neoplasms
193
Prostatic Neoplasms
158
Multiple Myeloma
139
Neoplasm Metastasis
117
Melanoma
110
Colorectal Neoplasms
107
Leukemia, Myeloid, Acute
102
Lymphoma
99
Lung Neoplasms
94
Ovarian Neoplasms
85
Squamous Cell Carcinoma of Head and Neck
75
Lymphoma, Non-Hodgkin
74
Leukemia, Lymphocytic, Chronic, B-Cell
70
Pancreatic Neoplasms
64
Triple Negative Breast Neoplasms
62
Myelodysplastic Syndromes
61
Parkinson Disease 4, Autosomal Dominant Lewy Body
60
Hematologic Neoplasms
59
Head and Neck Neoplasms
59
Recurrence
56
Glioblastoma
55
Leukemia
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
51
Sarcoma
49
Brain Neoplasms
49
Carcinoma, Hepatocellular
48
Lymphoma, Large B-Cell, Diffuse
47
Lymphoma, Follicular
46
Interventions
sitravatinib
1
Nivolumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Non-Squamous Non-Small Cell Lung Cancer
×
1 year
×
Clear all
NCT03906071
2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3
Completed
577 enrolled
22 charts